What Transcend Therapeutics does

Transcend Therapeutics is a clinical-stage biotechnology company founded in 2021 and headquartered in New York City, developing rapid-acting neuroplastogen treatments for neuropsychiatric diseases. The company's core asset is TSND-201 (methylone), an oral proprietary formulation that acts as a triple reuptake inhibitor and releaser of serotonin, norepinephrine, and dopamine, rapidly inducing BDNF-mediated neuroplasticity without hallucinogenic activity (no 5-HT2A receptor binding) and with compatibility for patients on SSRIs. TSND-201 is currently in Phase 3 development for PTSD following FDA Breakthrough Therapy Designation (July 2025) and a Commissioner's National Priority Voucher (April 2026), supported by positive Phase 2 IMPACT-1 data published in JAMA Psychiatry showing a -9.64 placebo-adjusted CAPS-5 improvement at Day 64.

The company's pipeline also targets Major Depressive Disorder and Generalized Anxiety Disorder, with next-generation prodrug candidates classified as new chemical entities in preclinical development. Leadership includes Blake Mandell (Co-founder/CEO, ex-BCG and AlleyCorp), Kevin Ryan (Co-founder/Chairman, AlleyCorp founder and MongoDB/Business Insider co-founder), Benjamin Kelmendi, MD (Co-founder/Chief Scientific Advisor, Yale), Martin Stogniew, PhD (Chief Development Officer, holder of 40 patents), and Amanda Jones, PharmD (SVP Clinical Development, former Axsome Therapeutics). The team is credited with contributions to 14 FDA approvals and $7 billion in M&A and public company value.

Transcend operates as a pre-revenue, clinical-stage company. Its $40 million Series A (February 2023) was co-led by Alpha Wave Global and Integrated Investment Partners, with the company emerging from stealth with approximately $42 million in total funding. A $1 million collaborative grant from the U.S. Department of Defense (September 2023) funded preclinical research with Yale University. On June 12, 2026, Otsuka America Inc. completed acquisition of Transcend for $700 million upfront plus up to $525 million in sales milestone payments (total up to $1.225 billion), making Transcend a wholly owned subsidiary of Otsuka Pharmaceutical. Post-acquisition, Transcend's commercial distribution will leverage Otsuka's established global pharmaceutical infrastructure.

Name

Transcend Therapeutics

Legal name

Transcend Therapeutics, Inc.

Website

https://transcendtherapeutics.com

Company type

Private

Founded year

2021

Operating status

Acquired

Headcount range

11–50 employees

Short description

Transcend Therapeutics is a clinical-stage biotechnology company developing TSND-201 (methylone), a rapid-acting non-hallucinogenic neuroplastogen in Phase 3 trials for PTSD, targeting the 13 million Americans affected annually. Acquired by Otsuka Pharmaceutical in June 2026 for up to $1.225 billion.

Ownership category

akta.pro rank

Product category

Neuropsychiatric Therapeutics

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Neuropsychiatric drug development
• PTSD therapeutics
• Clinical-stage biotechnology
• Rapid-acting neuroplastogens
• CNS disorder treatments

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Revenue: Pre-commercial stage. Transcend Therapeutics was acquired by Otsuka Pharmaceutical in June 2026 for $700 million upfront plus up to $525 million in milestone payments. Revenue will come from future sales of TSND-201 (methylone) if approved by FDA for PTSD and other indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Transcend Therapeutics is developing TSND-201 (methylone), a proprietary oral rapid-acting neuroplastogen for the treatment of Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other CNS indications. The compound acts as a triple monoamine reuptake inhibitor and releaser that induces neuroplasticity without hallucinogenic effects. The company is also advancing a pipeline of next-generation prodrug analogs classified as new chemical entities for broader neuropsychiatric indications.

Product overview

Transcend Therapeutics is a clinical-stage biotechnology company developing a portfolio of rapid-acting neuroplastogen treatments for neuropsychiatric diseases. The company's core product is TSND-201 (methylone), an oral neuroplastogen currently in Phase 3 development for PTSD with FDA Breakthrough Therapy designation. TSND-201 works by enhancing neuroplasticity through monoamine release without hallucinogenic effects. The company is also developing next-generation analogs (novel prodrugs) for broader CNS disorders including Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). Transcend operated as an independent company from 2021 until its acquisition by Otsuka Pharmaceutical in June 2026.

Differentiator

Problem solved

Functional benefit

Products and services

• TSND-201 (Methylone) TSND-201 is a proprietary oral formulation of methylone, a rapid-acting neuroplastogen being developed for the treatment of Post-Traumatic Stress Disorder (PTSD). It acts on monoamine transporters (serotonin, norepinephrine, dopamine) and induces neuroplasticity without hallucinogenic effects (no 5-HT2A activity). It is currently in Phase 3 clinical trials for PTSD with Breakthrough Therapy designation from the FDA, and is being evaluated for Major Depressive Disorder and other CNS indications.
• Next-Generation Prodrug Analogs Novel prodrug candidates classified as new chemical entities being developed to further improve the balance of efficacy, safety, and tolerability compared to TSND-201. Currently in preclinical stage with non-clinical studies underway in preparation for IND application for CNS disorders including generalized anxiety disorder and other indications.

Quantifiable outcome

• TSND-201 demonstrated -9.64 placebo-adjusted CAPS-5 improvement at Day 64 (p=0.011), meeting the primary endpoint of the IMPACT-1 Phase 2 study.
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Yale UniversitycoreStrategic or Co-development Partner · 21 September 2023Collaborative research grant with Yale University funded by the U.S. Department of Defense ($1 million over 3 years). Yale researchers are conducting preclinical studies using state-of-the-art microscopy and behavioral methods to understand the neurobiological mechanism underlying methylone's rapid-acting, long-lasting effects in PTSD. Co-founded by Dr. Benjamin Kelmendi, co-director of the Yale Program for Psychedelic Science.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Lykos Therapeutics (MAPS Public Benefit Corporation): Most direct competitor: developing MDMA-assisted therapy for PTSD, the same lead indication as Transcend's TSND-201. Comparability is high in target indication and patient population, though Lykos uses a classical psychedelic with hallucinogenic effects, whereas TSND-201 is non-hallucinogenic.
• Compass Pathways: Clinical-stage company developing psilocybin therapy for treatment-resistant depression, with an adjacent psychiatric focus to Transcend's MDD/anxiety pipeline. Both operate in the psychedelic/neuroplastogen therapeutic category and pursue regulatory pathways in CNS.
• GH Research: Clinical-stage company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparability in mechanism class (rapid-acting tryptamine/serotonergic) and CNS indication strategy is high.
• MindMed: Clinical-stage company developing psychedelic-inspired medicines (e.g., MM-120, MDMA derivatives) for anxiety, ADHD, and other CNS disorders. Operates in the same rapid-acting neuroplastogen category as Transcend with overlapping target indications.
• Atai Life Sciences: Holding company with multiple subsidiaries developing psychedelic-based therapies for mental health (depression, PTSD, anxiety). Portfolio approach is comparable to Transcend's emerging prodrug platform strategy, both addressing the same psychedelic therapeutics market.

Broad incumbents

• Axsome Therapeutics: Commercial-stage CNS company with Auvelity (dextromethorphan-bupropion) approved for major depressive disorder. Comparable as a focused CNS innovator with rapid-acting mechanisms and overlapping MDD target; SVP Clinical Development Amanda Jones led Auvelity's development at Axsome before joining Transcend.
• Sage Therapeutics: Commercial-stage CNS company with Zurzuvae approved for postpartum depression. Comparable as an established CNS-focused biopharma developing novel mechanisms for depression and other neuropsychiatric indications served by Transcend.
• Johnson & Johnson (Janssen): Large pharmaceutical company marketing Spravato (esketamine) for treatment-resistant depression — the only FDA-approved rapid-acting antidepressant and a direct competitor to TSND-201 in mechanism class and indication. Brings established CNS commercial infrastructure.
• Intra-Cellular Therapies: Commercial-stage CNS company with Caplyta (lumateperone) approved for schizophrenia and bipolar depression. Comparable as a focused CNS innovator with overlapping psychiatry indications and demonstrated ability to take novel CNS mechanisms through FDA approval.

Emerging players

• Delix Therapeutics: Clinical-stage company developing non-hallucinogenic neuroplastogens (e.g., DLX-1) for depression, PTSD, and other CNS disorders. Highly comparable mechanism and indication strategy to Transcend's TSND-201 and next-generation prodrug platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/transcend-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Transcend Therapeutics